AnaptysBio, Inc (ANAB) KPIs and segments

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30

$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $1.73BP/E –Yield –

KPIs & segments

Operating metrics and segments that drive AnaptysBio's business

AnaptysBio's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q2 2026	Q1 2026	Q1 2025

Royalty Management($M)	27.5	25.6	27.8
Biopharma($M)		0	0

Royalty Management($M)	14.1	18.2	23.7
Biopharma($M)		-52.8	-51.3

Royalty Management($M)	-2.73	-2.36	7.91
Biopharma($M)		-50.5	-47.2

Royalty Management($M)	179	-2.40	7.87
Biopharma($M)		-50.5	-47.2

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2026-09-21.

See a number that looks wrong?